Literature DB >> 11160159

Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression.

P K Epling-Burnette1, J H Liu, R Catlett-Falcone, J Turkson, M Oshiro, R Kothapalli, Y Li, J M Wang, H F Yang-Yen, J Karras, R Jove, T P Loughran.   

Abstract

Large granular lymphocyte (LGL) leukemia is characterized by the expansion of antigen-activated cytotoxic T lymphocytes. These leukemic cells are resistant to Fas-mediated apoptosis despite expressing high levels of Fas. We found that leukemic LGL from 19 patients displayed high levels of activated STAT3. Treatment of leukemic LGL with the JAK-selective tyrosine kinase inhibitor AG-490 induced apoptosis with a corresponding decrease in STAT-DNA binding activity. Moreover, using an antisense oligonucleotide approach to diminish STAT3 expression, we found that Fas sensitivity was restored in leukemic LGL. AG-490-induced apoptosis in leukemic LGL was independent of Bcl-xL or Bcl-2 expression. However, we found that the Bcl-2-family protein Mcl-1 was significantly reduced by AG-490 treatment. Activated STAT3 was shown to bind an SIE-related element in the murine mcl-1 promoter. Using a luciferase reporter assay, we demonstrated that v-src overexpression in NIH3T3 induced STAT3-dependent transcriptional activity from the mcl-1 promoter and increased endogenous Mcl-1 protein levels. We conclude that STAT3 activation contributed to accumulation of the leukemic LGL clones. These findings suggest that investigation should focus on novel strategies targeting STAT3 in the treatment of LGL leukemia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160159      PMCID: PMC199188          DOI: 10.1172/JCI9940

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  58 in total

1.  STAT3 regulates the growth and immunoglobulin production of BCL(1) B cell lymphoma through control of cell cycle progression.

Authors:  J G Karras; R A McKay; T Lu; J Pych; D A Frank; T L Rothstein; B P Monia
Journal:  Cell Immunol       Date:  2000-06-15       Impact factor: 4.868

2.  HTLV infection and hematologic malignancies.

Authors:  T P Loughran
Journal:  Leuk Res       Date:  1996-06       Impact factor: 3.156

3.  Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor.

Authors:  N Meydan; T Grunberger; H Dadi; M Shahar; E Arpaia; Z Lapidot; J S Leeder; M Freedman; A Cohen; A Gazit; A Levitzki; C M Roifman
Journal:  Nature       Date:  1996-02-15       Impact factor: 49.962

4.  The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance.

Authors:  L Van Parijs; A Ibraghimov; A K Abbas
Journal:  Immunity       Date:  1996-03       Impact factor: 31.745

5.  The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis.

Authors:  G Semenzato; R Zambello; G Starkebaum; K Oshimi; T P Loughran
Journal:  Blood       Date:  1997-01-01       Impact factor: 22.113

6.  Cell membrane expression and functional role of the p75 subunit of interleukin-2 receptor in lymphoproliferative disease of granular lymphocytes.

Authors:  R Zambello; L Trentin; G Pizzolo; P Bulian; M Masciarelli; C Feruglio; C Agostini; R Raimondi; T Chisesi; G Semenzato
Journal:  Blood       Date:  1990-11-15       Impact factor: 22.113

7.  Activation of leukemic large granular lymphocytes by interleukin-2 via the p75 interleukin-2 receptor.

Authors:  H J Yoon; K Sugamura; T P Loughran
Journal:  Leukemia       Date:  1990-12       Impact factor: 11.528

8.  The SIF binding element confers sis/PDGF inducibility onto the c-fos promoter.

Authors:  B J Wagner; T E Hayes; C J Hoban; B H Cochran
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

9.  Anti-CD3 monoclonal antibody-mediated cytotoxicity occurs through an interleukin-2-independent pathway in CD3+ large granular lymphocytes.

Authors:  T P Loughran; J A Aprile; F W Ruscetti
Journal:  Blood       Date:  1990-02-15       Impact factor: 22.113

10.  STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients.

Authors:  V Gouilleux-Gruart; F Gouilleux; C Desaint; J F Claisse; J C Capiod; J Delobel; R Weber-Nordt; I Dusanter-Fourt; F Dreyfus; B Groner; L Prin
Journal:  Blood       Date:  1996-03-01       Impact factor: 22.113

View more
  221 in total

Review 1.  Stat proteins and oncogenesis.

Authors:  Jacqueline Bromberg
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

2.  STAT3 Inhibition Induces Apoptosis in Cancer Cells Independent of STAT1 or STAT2.

Authors:  Adetola Shodeinde; Kalyani Ginjupalli; H Dan Lewis; Sheraz Riaz; Beverly E Barton
Journal:  J Mol Biochem       Date:  2013-02-20

3.  B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation.

Authors:  Hao Liu; Christina Tekle; Yih-Wen Chen; Alexandr Kristian; Yuhua Zhao; Ming Zhou; Zixing Liu; Yan Ding; Bin Wang; Gunhild Mari Mælandsmo; Jahn Marthin Nesland; Oystein Fodstad; Ming Tan
Journal:  Mol Cancer Ther       Date:  2011-04-25       Impact factor: 6.261

4.  Dietary compounds as potent inhibitors of the signal transducers and activators of transcription (STAT) 3 regulatory network.

Authors:  Anne Trécul; Franck Morceau; Mario Dicato; Marc Diederich
Journal:  Genes Nutr       Date:  2012-01-25       Impact factor: 5.523

Review 5.  Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis.

Authors:  Okkyung Rho; Dae Joon Kim; Karou Kiguchi; John Digiovanni
Journal:  Mol Carcinog       Date:  2010-07-20       Impact factor: 4.784

Review 6.  Mature T-cell leukemias: Molecular and Clinical Aspects.

Authors:  Nathanael G Bailey; Kojo S J Elenitoba-Johnson
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

7.  Antigen activation and impaired Fas-induced death-inducing signaling complex formation in T-large-granular lymphocyte leukemia.

Authors:  Jun Yang; P K Epling-Burnette; Jeffrey S Painter; Jianxiang Zou; Fanqi Bai; Sheng Wei; Thomas P Loughran
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

Review 8.  Preclinical studies of novel targeted therapies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

Review 9.  Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia.

Authors:  HeeJin Cheon; Karolina H Dziewulska; Katharine B Moosic; Kristine C Olson; Alejandro A Gru; David J Feith; Thomas P Loughran
Journal:  Curr Hematol Malig Rep       Date:  2020-04       Impact factor: 3.952

10.  Cryptotanshinone, a Stat3 inhibitor, suppresses colorectal cancer proliferation and growth in vitro.

Authors:  Weidong Li; Shakir M Saud; Matthew R Young; Nancy H Colburn; Baojin Hua
Journal:  Mol Cell Biochem       Date:  2015-04-26       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.